WILMINGTON, DE — Incyte (Nasdaq: INCY) said it will present at the 44th Annual J.P. Morgan Healthcare Conference on Monday, January 12, 2026, placing the biopharmaceutical company in front of investors at one of the industry’s most influential annual gatherings.
The presentation is scheduled for 8:15 a.m. Pacific Time and will be webcast live through the company’s investor relations website. A replay will be available for 30 days following the event.
Incyte’s appearance comes as investors continue to closely monitor developments across the company’s oncology and inflammation and autoimmunity pipeline, areas that have driven its long-term growth strategy. The conference is widely viewed as a forum where companies outline clinical progress, regulatory milestones, and strategic priorities for the year ahead.
Headquartered in Wilmington, Delaware, Incyte is a global biopharmaceutical company focused on discovering, developing, and commercializing proprietary medicines for patients with unmet medical needs. The company has built a portfolio of first-in-class therapies and maintains a broad pipeline spanning oncology and immune-mediated diseases, with operations across North America, Europe, and Asia.
The J.P. Morgan Healthcare Conference is considered a bellwether event for the sector, often shaping market expectations and investor sentiment for the year.
For the latest news on everything happening in Chester County and the surrounding area, be sure to follow MyChesCo on Google News and MSN.